Bibliography
- DiMasi JA , HansenRW, GrabowskiHG: The price of innovation: new estimates of drug development costs.J. Health Econ.22 , 151–185 (2003).
- Wood AJ : A proposal for radical changes in the drug-approval process.N. Engl. J. Med.355(6) , 618–623 (2006).
- Kapp AV , JeffreySS, LangerodA et al.: Discovery and validation of breast cancer subtypes.BMC Genom.11(7) , 231 (2006).
- Maher PD , HaffnerM: Orphan drug designation and pharmacogenomics: options and opportunities.BioDrugs20(2) , 71–79 (2006).
- Lasko TA , BhagwatJG, ZouKH, Ohno-MachadoL: The use of receiver operating characteristic curves in biomedical informatics.J. Biomed. Inform.38(5) , 404–415 (2005).
- Lesko LJ : Paving the critical path: how can clinical pharmacology help achieve the vision?Clin. Pharmacol. Ther.81 , 170–177 (2007).
- Munos B : Can open-source R&D reinvigorate drug research?Nat. Rev. Drug Discov.5(9) , 723–729 (2006).
- Taylor WC , LaBarrePG: Mavericks at Work: Why the Most Original Minds in Business Win. Harper Collins Publishers, NY, USA (2006).
▪ Websites
- US FDA: FDA news – advancing america‘s health. Advancing medical breakthroughs. “Critical Path” paper calls for academic researchers, product developers, and patient groups to work with FDA to help identify opportunities to modernize tools for speeding approvable, innovative products to improve public health (2004) www.fda.gov/bbs/topics/news/2004/NEW01035.html
- US FDA: FDA news – FDA unveils critical path opportunities list outlining blueprint to modernizing medical product development by 2010 (2006) www.fda.gov/bbs/topics/news/2006/NEW01336.html
- Smith A: From orphan to blockbuster? Biotechs lead the way in getting orphan drugs to market, and sometimes they actually make money. CNN Money (2005) http://money.cnn.com/2005/07/08/news/midcaps/orphan/index.htm
- Affymetrix Inc.: Affymetrix Reports fourth quarter and fiscal year 2005 Results; consumables drive revenue growth (2006) www.corporate-ir.net/ireye/ir_site.zhtml?ticker=AFFX&script=410&item_id=809172&sstring=clia&layout=23
- Gray Haupt C: Clinical research organizations expand speed and capacity of pharmaceuticals‘ product development pipeline, Tufts study finds. ACRO (2006) www.acrohealth.org/press-release-detail.php?serial=20
- Open Source Initiative www.opensource.org/
- InnoCentive Inc. www.innocentive.com
- NineSigma Inc. www.ninesigma.com
- X Prize Foundation http://genomics.xprize.org/
- US FDA: FDA News – FDA and the Critical Path Institute announce predictive safety testing consortium (2006) www.fda.gov/bbs/topics/news/2006/NEW01337.html
- European Medicines Agency; Committee For Human Medicinal Products: final report on the Pilot Joint EMEA/FDA VXDS experience on qualification of nephrotoxicity biomarkers. European Medicines Agency, London, UK (2008) www.emea.europa.eu/pdfs/human/biomarkers/25088508en.pdf
- Foundation for the National Institutes of Health www.fnih.org/index.php?option=com_content&task=view&id=170&Itemid=43